Siebert Reports 2025 Financial Results

Siebert Financial Corp. (SIEB) announced a leadership restructuring, with John J. Gebbia becoming Chairman and his sons John M., David, and Richard taking expanded executive roles. The company reported $31.2M in Q2 2026 revenue and is expanding into new financial services. The changes mark a generational shift as the company approaches its 60th year.

Stifel reduced its price target for Contineum Therapeutics (CTNM) to $23 from $28, maintaining a Buy rating. The stock trades at $10.17, with analysts' targets ranging from $14 to $30. The company's phase 2 study for idiopathic pulmonary fibrosis is ongoing, with data expected in 2028. CTNM has a strong financial position, according to InvestingPro. Recent trial results and analyst actions present a mixed outlook.

UBS maintained a Buy rating and $230 price target on 3M (NYSE:MMM) after its $5.8B PFAS settlement and $6B share buyback plan. The stock rose near its 52-week high, up 26% in six months. Analysts have mixed views on 3M's performance and outlook.

Ford's U.S. sales fell 0.8% YoY in October, but its current lineup saw a 6.9% increase. F-Series trucks and large SUVs drove gains, with F-Series up 8.2% and Explorer up 25%. Ford EVs declined 71% YoY. Lincoln's sales rose 35% excluding the discontinued Corsair. Other automakers like Honda, Hyundai, and Kia reported sales increases for October.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels

Oncolytics Biotech (ONCY) reported that pelareorep increased HPV-16-specific T-cell and tumor-infiltrating lymphocyte clones in a study of anal cancer patients. The company also noted efficacy signals compared to current therapies, but did not provide specific response rates.